Review
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney

https://doi.org/10.2133/dmpk.24.37Get rights and content

Summary:

Transporter govern drug movement into and out of tissues, thereby playing an important role in drug disposition in plasma and to the site of action. The molecular cloning of such transporters has clarified the importance of members of the solute carrier family, such as OATP/SLCO, OCT/SLC22, OAT/SLC22, and MATE/SLC47, and the ATP-binding cassette transporters, such as P-glycoprotein/ABCB1, MRPs/ABCC, and BCRP/ABCG2. Elucidation of molecular characteristics of transporters has allowed the identification of transporters as mechanisms for drug-drug interactions, and of interindividual differences in drug dispositions and responses. Cumulative studies have highlighted the cooperative roles of uptake transporters and metabolic enzymes/efflux transporters. In this way, the concept of a rate-limiting process in hepatic/renal elimination across epithelial cells has developed. This review illustrates the concept of the rate-limiting step in the hepatic elimination mediated by transporters, and describes the prediction of the in vivo pharmacokinetics of drugs whose disposition is determined by transporters, based on in vitro experiments using pravastatin as an example. This review also illustrates the transporters regulating the peripheral drug concentrations.

References (113)

  • M. Huls et al.

    The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane

    Kidney. Int.

    (2008)
  • M. Takano et al.

    Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles

    Biochim. Biophys. Acta.

    (1984)
  • I. Tamai et al.

    Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1

    FEBS Lett.

    (1997)
  • Y. Tanihara et al.

    Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H( + )-organic cation antiporters

    Biochem. Pharmacol.

    (2007)
  • A.H. Schinkel et al.

    Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs

    Cell

    (1994)
  • Y.J. Lee et al.

    In Vivo Evaluation of P-glycoprotein Function at the Blood–brain Barrier in Nonhuman Primates Using [11C]Verapamil

    J. Pharmacol. Exp. Ther.

    (2006)
  • Giacomini, K. M. and Sugiyama, Y.: Membrane transporters and drug response. In L. L. Brunton, J. S. Lazo, K. L. Parker,...
  • R. Masereeuw et al.

    Mechanisms and clinical implications of renal drug excretion

    Drug Metab. Rev.

    (2001)
  • Y. Shitara et al.

    Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

    Annu. Rev. Pharmacol. Toxicol.

    (2005)
  • R.S. Obach

    Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes

    Drug Metab. Dispos.

    (1999)
  • Watanabe, T., Kusuhara, H., Maeda, K., et al.: Physiologically based pharmacokinetic modeling to predict...
  • K. Ueda et al.

    Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data

    J. Pharmacol. Exp. Ther.

    (2001)
  • Y. Kitamura et al.

    Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3)

    (2008)
  • S. Miyauchi et al.

    Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers

    Pharm Res

    (1993)
  • M. Yamazaki et al.

    Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter

    Drug Metab. Dispos.

    (1997)
  • X. Liu et al.

    Use of Ca2 + modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes

    J. Pharmacol. Exp. Ther.

    (1999)
  • K. Abe et al.

    In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance

    J. Pharmacol. Exp. Ther.

    (2008)
  • H. Fukuda et al.

    Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes

    Drug Metab. Dispos.

    (2008)
  • B.G. Reigner et al.

    An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development

    Experience within Hoffmann La Roche. Clin. Pharmacokinet.

    (1997)
  • J.H. Lin

    Species similarities and differences in pharmacokinetics

    Drug Metab. Dispos.

    (1995)
  • Y. Nozaki et al.

    Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices

    J. Pharmacol. Exp. Ther.

    (2007)
  • Y. Nozaki et al.

    Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices

    J. Pharmacol. Exp. Ther.

    (2007)
  • M. Hasegawa et al.

    Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions

    J. Pharmacol. Exp. Ther.

    (2002)
  • M. Hasegawa et al.

    Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat

    J. Pharmacol. Exp. Ther.

    (2003)
  • W. Haase et al.

    Studies on the orientation of brush-border membrane vesicles

    Biochem. J.

    (1978)
  • M. Hirano et al.

    Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic up-take of pitavastatin in humans

    J. Pharmacol. Exp. Ther.

    (2004)
  • N. Ishiguro et al.

    Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans

    Drug Metab. Dispos.

    (2006)
  • M.K. Pasanen et al.

    SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Pharmacogenet. Genomics.

    (2006)
  • M. Niemi et al.

    Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

    Clin. Pharmacol. Ther.

    (2005)
  • A. Kalliokoski et al.

    Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

    J. Clin. Pharmacol.

    (2008)
  • M.K. Pasanen et al.

    Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin

    Clin. Pharmacol. Ther.

    (2007)
  • Y. Shitara et al.

    Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A

    J. Pharmacol. Exp. Ther.

    (2003)
  • Y.Y. Lau et al.

    effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

    Clin. Pharmacol. Ther.

    (2007)
  • I. Ieiri et al.

    SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers

    Clin. Pharmacol. Ther.

    (2007)
  • Y. Nishizato et al.

    Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

    Clin. Pharmacol. Ther.

    (2003)
  • K. Maeda et al.

    Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril

    Clin. Pharmacol. Ther.

    (2006)
  • E. Link et al.

    SLCO1B1 variants and statin-induced myopathy–a genomewide study

    N. Engl. J. Med.

    (2008)
  • M. Niemi et al.

    Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17

    Pharmacogenet. Genomics.

    (2005)
  • H. Takane et al.

    Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy

    J. Hum. Genet.

    (2006)
  • M. Igel et al.

    Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

    Clin. Pharmacol. Ther.

    (2006)
  • Cited by (194)

    • Effect of liver disease on pharmacokinetics

      2021, Atkinson's Principles of Clinical Pharmacology
    View all citing articles on Scopus
    View full text